News | June 24, 2022
Silo Pharma expands license agreement and patent portfolio
Silo enters into commercial evaluation license agreement for next generation liposomes
Silo enters into commercial evaluation license agreement for next generation liposomes
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
Subscribe To Our Newsletter & Stay Updated
